Underexpression of MMP-2 and its regulators, TIMP2, MT1-MMP and IL-8, is associated with prostate cancer

International Braz J Urol

Volumn 38, Issue 2, 2012, Pages 167-174

  Reis, Sabrina Thalita ^a   Antunes, Alberto Azoubel ^a   Pontes Junior, Jose ^a   de Sousa Canavez, Juliana Moreira ^b   Dall'Oglio, Marcos Francisco ^a   Piantino, Camila Belfort ^a   da Cruz, Jose Arnaldo Shiomi ^a   Reis Morais, Denis ^a   Srougi, Miguel ^a   Leite, Katia R M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Genoa Biotechnology SA   (Brazil)

Author keywords

Diagnosis; Gene expression; Matrix metalloproteinase; Neoplasms; Prognosis; Prostate

Indexed keywords

GELATINASE A; INTERLEUKIN 8; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; BLOOD; CANCER GRADING; COMPARATIVE STUDY; GENE EXPRESSION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE HYPERTROPHY; PROSTATE TUMOR; PROSTATECTOMY; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; GENE EXPRESSION; HUMANS; INTERLEUKIN-8; MALE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM GRADING; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 84865356275     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382012000200004     Document Type: Article

References (27)

1. Siegel R, Ward E, Brawley O, Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61: 212-36.
2. Berger AP, Spranger R, Kofler K, Steiner H, Bartsch G, Horninger W: Early detection of prostate cancer with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimens. Prostate. 2003; 57: 93-8.
3. Toi M, Ishigaki S, Tominaga T: Metalloproteinases and tissue inhibitors of metalloproteinases. Breast Cancer Res Treat. 1998; 52: 113-24.
4. Eissa S, Ali-Labib R, Swellam M, Bassiony M, Tash F, El-Zayat TM: Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. Eur Urol. 2007; 52: 1388-96.
5. Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F: Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res. 1996; 56: 190-6.
6. Sato H, Takino T, Kinoshita T, Imai K, Okada Y, Stetler Stevenson WG et al.: Cell surface binding and activation of gelatinase A induced by expression of membrane-type- 1-matrix metalloproteinase (MT1-MMP). FEBS Lett. 1996; 385: 238-40.
7. Jovanovic M, Stefanoska I, Radojcic L, Vicovac L. Interleukin- 8 (CXCL8) stimulates trophoblast cell migration and invasion by increasing levels of matrix metalloproteinase (MMP)2 and MMP9 and integrins alpha5 and beta1. Reproduction. 2010; 139: 789-98.
8. Henriet P, Blavier L, Declerck YA. Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation. APMIS. 1999; 107: 111-9.
9. Nawrocki B, Polette M, Marchand V, Monteau M, Gillery P, Tournier JM et al.: Expression of matrix metalloproteinases and their inhibitors in human bronchopulmonary carcinomas: quantificative and morphological analyses. Int J Cancer. 1997; 72: 556-64.
10. Polette M, Nawrocki-Raby B, Gilles C, Clavel C, Birembaut P: Tumour invasion and matrix metalloproteinases. Crit Rev Oncol Hematol. 2004; 49: 179-86.
11. Tang ZG, Li JM, Hong ZZ, Yu ZW, Liu CH: Expression of matrix metalloproteinase 2 in oral verruvous carcinoma and squamous cell carcinoma. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2005; 30: 650-2.
12. Scrideli CA, Cortez MA, Yunes JA, Queiróz RG, Valera ET, da Mata JF et al.: mRNA expression of matrix metalloproteinases (MMPs) 2 and 9 and tissue inhibitor of matrix metalloproteinases (TIMPs) 1 and 2 in childhood acute lymphoblastic leukemia: potential role of TIMP1 as an adverse prognostic factor. Leuk Res. 2010; 34: 32-7.
13. Balbín M, Fueyo A, Tester AM, Pendás AM, Pitiot AS, Astudillo A et al.: Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet. 2003; 35: 252-7.
14. Lichtinghagen R, Musholt PB, Lein M, Römer A, Rudolph B, Kristiansen G et al.: Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. Eur Urol. 2002; 42: 398-406.
15. Brehmer B, Biesterfeld S, Jakse G. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue. Prostate Cancer Prostatic Dis. 2003; 6: 217-22.
16. Moreira Leite KR, Camara-Lopes LH, Dall'Oglio MF, Cury J, Antunes AA, Sañudo A et al.: Upgrading the Gleason score in extended prostate biopsy: implications for treatment choice. Int J Radiat Oncol Biol Phys. 2009; 73: 353-6.
17. Zhong WD, Han ZD, He HC, Bi XC, Dai QS, Zhu G et al.: CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer. Oncology. 2008; 75: 230-6.
18. Simi L, Andreani M, Davini F, Janni A, Pazzagli M, Serio M et al.: Simultaneous measurement of MMP9 and TIMP1 mRNA in human non small cell lung cancers by multiplex real time RT-PCR. Lung Cancer. 2004; 45: 171-9.
19. Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002; 2: 161-74.
20. Miyake H, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M: Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol Oncol. 2010; 28: 145-51.
21. Cox G, Jones JL, Walker RA, Steward WP, O'Byrne KJ. Angiogenesis and non-small cell lung cancer. Lung Cancer. 2000; 27: 81-100.
22. Rabbani SA, Harakidas P, Guo Y, Steinman D, Davidsen SK, Morgan DW: Synthetic inhibitor of matrix metalloproteases decreases tumor growth and metastases in a syngeneic model of rat prostate cancer in vivo. Int J Cancer. 2000; 87: 276-82.
23. Nemeth JA, Rafe A, Steiner M, Goolsby CL. TIMP-2 growthstimulatory activity: a concentration- and cell type-specific response in the presence of insulin. Exp Cell Res. 1996; 224: 110-5.
24. Murashige M, Miyahara M, Shiraishi N, Saito T, Kohno K, Kobayashi M: Enhanced expression of tissue inhibitors of metalloproteinases in human colorectal tumors. Jpn J Clin Oncol. 1996; 26: 303-9.
25. Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O: High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res. 1997; 3: 1623-8.
26. Grignon DJ, Sakr W, Toth M, Ravery V, Angulo J, Shamsa F et al.: High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res. 1996; 56: 1654-9.
27. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI: Mechanism of cell surface activation of 72- kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem. 1995; 270: 5331-8.